

pDUO-hCD14/TLR2

A plasmid coexpressing the human CD14 and TLR2 genes

Catalog code: pduo-hcd14tlr2

<https://www.invivogen.com/pduo-cd14-tlr2>

For research use only

Version 20H25-MM

PRODUCT INFORMATION

Contents

- 20 µg of pDUO-hCD14/TLR2 provided as DNA
- 2 x 1 ml blasticidin at 10 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

Toll-Like receptors (TLRs) play a critical role in early innate immunity to invading pathogens by sensing microorganisms. These evolutionary conserved receptors, homologues of the Drosophila Toll gene, recognize highly conserved structural motifs only expressed by microbial pathogens, called pathogen-associated microbial patterns (PAMPs). PAMPs include various bacterial cell wall components such as lipopolysaccharides (LPS), peptidoglycans and lipopeptides, as well as flagellin, bacterial DNA and viral double-stranded RNA. Stimulation of TLRs by PAMPs initiates a signaling cascade that involves a number of proteins, such as MyD88 and IRAK. This signaling cascade leads to the activation of the transcription factor NF-κB which induces the secretion of pro-inflammatory cytokines and effector cytokines that direct the adaptive immune response.

To date ten human and twelve murine TLRs have been characterized, TLR1 to TLR10 in humans, and TLR1 to TLR9, TLR11, TLR12 and TLR13 in mice, the homolog of TLR10 being a pseudogene. In many instances, TLRs require the presence of a co-receptor to initiate the signaling cascade. One example is TLR4 which interacts with MD2 and CD14 to induce NF-κB in response to LPS stimulation.

pDUO is an expression vector designed to co-express two TLRs or TLR-related genes known to interact with each other.

The genes cloned into pDUO comprise the coding sequence (without introns) from the ATG to the Stop codon.

PLASMID FEATURES

- **Human CD14 (1125 bp) / Human TLR2 (2352 bp)**
TLR2 is involved in the recognition of multiple products of Gram-positive bacteria, mycobacteria and yeast. The first studies reported that TLR2 mediated LPS response but TLR2 has since been shown to confer responsiveness to the lipopeptides present in LPS preparations. However, it seems that some types of LPS can activate TLR2¹. TLR2 is known to heterodimerize with other TLRs, a property believed to extend the range of PAMPs that TLR2 can recognize. TLR2 cooperates with TLR6 in the response to peptidoglycan² and diacylated mycoplasmal lipopeptide, and associates with TLR1 to recognize triacylated lipopeptides. Furthermore, pathogen recognition by TLR2 is strongly enhanced by CD14.
- **hFerH and hFerL composite promoters:** Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein³. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.
- **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range. The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells. Furthermore, the SV40 enhancer is able to direct nuclear localization of plasmids⁴.
- **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer⁵.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell et al.⁶
- **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

- **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁷.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Bsr (blasticidin resistance gene):** The *bsr* gene from *Bacillus cereus* encodes a deaminase that confers resistance to the antibiotic Blasticidin. In bacteria, *bsr* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *bsr* is transcribed from the human FerH composite promoter as a polycistronic mRNA and translated via the FMDV IRES.
- **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

References

- 1. Netea MG. et al., 2002.** Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? *Trends Immunol.* 23(3):135-9.
- 2. Ozinsky A. et al., 2000.** The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. *PNAS* 97(25):13766-71.
- 3. Eisenstein RS. & Munro HN. 1990.** Translational regulation of ferritin synthesis by iron. *Enzyme* 44(1-4):42-58.
- 4. Dean DA. et al., 1999.** Sequence requirements for plasmid nuclear import. *Exp. Cell. Res.* 253:713-22.
- 5. Boshart M. et al., 1985.** A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 141(2):521-30.
- 6. Carswell S. & Alwine JC. 1989.** Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258.
- 7. Ramesh N et al., 1996.** High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. *Nucleic Acids Res.* 24(14):2697-700.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



Sdal (6)
1 CCTGCAGGCGTTACATAACTTACGGTAATGGCCGCTGGCTACCGGCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCATAGTAA

NdeI (182)
101 CGCCAATAGGGACTTCCATTGACGTCAATGGGTGAGTATTACGGTAACACTGCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCC

SnaBI (288)
201 TATTGACGTCAATGACGGTAATGGCCGCTGGCATTATGCCAGTACATGACCTATGGACTTCTACTTGGCAGTACATCTACGTTAGTCAT

301 GCTATTACCATGATGCGGTTGGCAGTACATCAATGGCGTGATAGCGGTTGACTCACGGGATTCCAAGTCTCACCCATTGACGTCAATG

401 GGAGTTTGTGACTAGTCAGGGCCCAACCCCCCAAGCCCCATTCAACAACACGCTGGCCTACAGGCGGTGACTTCCCCTGTTGGCGGG

BspEI (520)
501 GGGCTGAGACTCCTATGTCTCCGATTGGTCAGGCACGGCCTCGGCCCGCCCTGCCACCGCAGATTGGCGCTAGGCCCTCCGAGCCTGCC

601 TCCGAGGGCCGGCGACCATAAAGAAGCCGCCCTAGCCACGTCCCTCGCAGTCGGCCTCGGGTCTGCTCAAGCTGGCCAGAACACAGG

701 taagtggcggtgtgtggccgcggcgtggcttacgggttatggcccttgctgcgtgaattacttcatggccctggctgcgtacgtgattc

801 ttgatcccggagttcgggttggaaagtgggtggagagttcgaggccttgcttaaggagccccctgcctcgctgagttggggctggcttggc

901 ctggggccgcgtgtaatctggggcacccgcgtgtctcgctgttcgtctaagtcttagccattaaattttgataaccagctgcacg

1001 cttttttctggcgagatgtttaatgcggccaggatctgcacactgttattcggtttttggggccggccgacggggccgtgcggcc

1101 agcgacatgttcggcgaggcgccccctgcgagcggccaccgagaatcgacggggtagtctcaactggccgcgtctggcgtgcgc

1201 gcccgggttatcgcgcgcgcggcaaggctggccggcaccagttgcgtgagcggaaagatggccgttccggccgtgcaggag

1301 tcaaatggaggacgcggcgccccggagagcggccgggtgagtcaccacacaaggaaaaggcccttcctcatcgctgcgtactcca

1401 cggagtagccggccgcgtccaggcacctcgatttgtcgagctttggagtagtcgtcttagttggggaggggtttatgcgtggagttc

DraIII (1509)
1501 ccacacttagtgggtggagactgaagagttaggccagttggacttgcattgtatctcattggaaatttgccttttagttggatctgcatttc

AgeI (1672)
1601 tcaaggcctcagacagttcaagtttttcttcatttcagGTGTCGTGAAAACCTAACCCCTAAAGCCACCGTAGGAGGCCAGCATGCCACATAC

1►MetProHisTh

1701 TTGATGGATGGTGTGGCTTGGGTCATCATCAGCTCTCAAGGAAGAACCTCAATCAGGCTCTCTGCTCTGACCCCAATGGTATCTGAAG
4►rLeuTrpMetVal TrpValLeuGlyValLeuSerLeuSerLysGluGluSerAsnGlnAlaSerLeuSerCysAspArgAsnGlyIleCysLys

Bsu36I (1830)
1801 GGCAGCTCAGGATCTTAACTCCATCCCTCAGGGCTCACAGAAGCTGAAAAAGCCTGACCTGTCACAGGATCACCTACATTGACACAGTG
38►GlySerSerGlySerLeuAsnSerIleProSerGlyLeuThrGluAlaValLysSerLeuAspLeuSerAsnArgIleThrTyrIleSerAsnSerA
1901 ACCTACAGAGGTGTGAACCTCCAGGGCTCTGGTGTGACATCCATGAAATTACACATGAGGAAAGATTCTTTCTCCCTGGCAGTCTGAAC
71►spLeuGlnArgCysValAsnLeuGlnAlaLeuValLeuThrSerAsnGlyIleAsnThrIleGluGluAspSerPheSerSerLeuGlySerLeuGluHi
2001 TTTAGACTTATCTATAATTACTTATCTAATTATCTGTTCTGTTCAAGCCCCCTTCTTAACTTAACTTACTGGAAATCCTAACAA
104►sLeuAspLeuSerTyrAsnTyrLeuSerAsnLeuSerSerTrpPheLysProLeuSerSerLeuThrPheLeuAsnLeuLeuGlyAsnProTyrLys
AvrII (2103)
2101 ACCCTAGGGAAACATCTTTTCTCATCTCACAAAATTGCAATCTGAGAGTGGAAATATGGACACCTTCACTAAGATTCAAAGAAAAGATTG
138►ThrLeuGlyGluUthrSerLeuPheSerHisLeuThrLysLeuGlnIleLeuArgValGlyAsnMetAspThrPheThrLysIleGlnArgLysAspPheA

BglIII (2241)
2201 CTGGACTTACCTCCTGAGGAACTTGAGATTGATGCTTCAGATCACAGAGCTATGAGCCTAGGAAAGTTGAAGTCATTGAGATGTTGGACACTT
171►IaGlyLeuThrPheLeuGluGluLeuGluIleAspAlaSerAspLeuGlnSerTyrGluProLysSerLeuLysSerIleGlnAsnValSerHiLeuI
NdeI (2306)
2301 CCTCATATGAAGCAGCATATTTACTGCTGGAGATTTTGAGATGTTGAGATGTTGAGATGTTGAGATGCTGGAACTGCGAGATACTGATTGGACACTT
204►eLeuHisMetLysGlnHisIleLeuLeuGluIlePheValAspValThrSerSerValGluCysLeuGluLeuArgAspThrAspLeuAspThrPhe
2401 CATTTCAGAACTATCCACTGGTGAACAAATTCTGATTTAGATAAAAGTTGAAATGTGAAATCACCGATGAAAGTTGTTGAGTT
238►HiSpheSerGlyLeuSerThrGlyLeuThrAsnSerLeuIleLysLysPheThrPheArgAsnValLysIleThrAspGluSerLeuPheGlnValMetL
2501 AACTTTGAATCAGATTCTGGATTGAGATTAGAGTTGACTGTACCTTAATGGAGTTGTAATTAGACATCTGATAATGACAGAGTT
271►ysLeuLeuAsnGlnIleSerGlyLeuLeuGluLeuGluPheAspAspCysThrLeuAsnGlyValGlyAsnPheArgAlaSerAspAsnAspArgValI
BspEI (2629)
Psp1406I (2620)
2601 AGATCCAGGAAAGCTTAAACATCCGGAGGCTGCATATTCAAGGTTTACTTATTGATCTGAGCACTTATTCACCTACAGAAAGA
304►eAspProGlyLysValGluThrLeuThrIleArgLeuHisIleProArgPheTyrLeuPheTyrAspLeuSerThrLeuTyrSerLeuThrGlyIleArg
2701 GTTAAAGAATCACAGTAGAAAACGATAAGTTTCTGGTCTGTTACTTCAACATTAACATTAGAAATCTGGATCTCAGTGAAATT
338►ValLysArgIleThrValGlyLeuAsnSerLysValPheLeuValProCysLeuLeuSerGlnHiLeuLysSerLeuGluTyrLeuAspLeuSerGluAsnL
2801 TGATGGTGAAGAATACTTGGGCTCTGAGGATGCTGGCCCTCTACAACTTAAAGGAAATCATTGGCATCATTGGAA
371►euMetValGluLeuGluTyrLeuLysAsnSerAlaCysGluAspAlaTrpProSerLeuGlnThrLeuIleLeuArgGlnAsnHiLeuAlaSerLeuGluI
EcoRV (2946)
2901 AACCGGAGAGACTTGTCACTCTGAAACATTGACTAACATTGATATCAGTAAGAATAGTTCTATTGCTGAAACTGTCAGTGGCAGAAAG
404►sThrGlyGluThrLeuLeuThrLeuLysAsnLeuThrAsnIleAspIleSerLysAsnSerPheHisSerMetProGluThrCysGlnTrpProGluLys
SspI (3007)
3001 ATGAAATTTGAACCTATCCAGCACAGAACATACAGTGTACAGGCTGCATTCCAAGACACTGGAAATTAGTGTAGCAACAACTCAATT
438►MetLysTyrLeuAsnLeuSerSerThrArgIleHisSerValThrGlyCysIleProLysThrLeuGluIleLeuAspValSerAsnAsnLeuAsnL
3101 TATTTCTTGAATTGCGCAACTCAAAGAACATTATTTCCAGAAATAAGTTGATGACTCTACAGATGCCCTCTTACCCATGTTACTAGATT
471►euPheSerLeuAsnLeuProGlnLeuLysGluLeuTyrIleSerArgAsnLysLeuMetThrLeuProAspAlaSerLeuLeuProMetLeuLeuValLe
3201 GAAAATCAGTAGGAATGCAATAACTACGTTCTAAGGAGCAACTTGACTCATTCACACACTGAAGACTTGGAGCTGTGCAATAACTCATTG
504►uLysIleSerArgAsnAlaIleThrThrPheSerLysGlyGluLeuAspSerPheHisThrLeuLysThrLeuGluAlaGlyAsnAsnPhelIleCys

